Drug Trial Radar · NCT02657005
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma
Last checked: Nov 19, 2026Latest source record: Feb 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
85
Actual
Start
Aug 2016
Primary completion
May 2022
Study completion Jun 2022
Sponsor
- Lead sponsor
- Oncternal Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ewing sarcoma is characterized by genomic rearrangements resulting in over-expression of ets family transcription factors driving tumor progression. TK216 is designed to inhibit this effect by inhibiting downstream effects of the EWS-FLI1 transcription factor. This study is a first in human study of TK216 in subjects with Ewing sarcoma. The study is designed to establish initial safety and efficacy data in monotherapy and in combination with vincristine to assess the potential of TK216 for further development.
Conditions
- Sarcoma, Ewing
Interventions
TK216Drug
Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: 36 months
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California
Children's Hospital of Colorado
Aurora, Colorado
Children's National Hospital
Washington D.C., District of Columbia
Memorial Sloan Kettering Cancer Center
New York, New York
Duke Cancer Institute
Durham, North Carolina
Cleveland Clinic Foundation
Cleveland, Ohio
Oregon Health & Science University
Portland, Oregon
Texas Children's Cancer & Hematology Centers, Baylor College
Houston, Texas
UT MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.